GoodRx (Foundayo + Zepbound KwikPen) vs ReadyRx
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
GoodRx (Foundayo + Zepbound KwikPen)
Best for self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmaciesStarting at $149/mo
ReadyRx
Best for compounded GLP-1 buyers who want LegitScript certification and explicit batch lab testing claims at a sub-$200 starting priceStarting at $179/mo
Side-by-Side Comparison
| Feature | GoodRx (Foundayo + Zepbound KwikPen) | ReadyRx |
|---|---|---|
| Overall Score | ✓8.4/10 | 7.2/10 |
| Starting Price | ✓$149/mo | $179/mo |
| Editorial Rating | ✓4.2 ★ /5 | 3.6 ★ /5 |
| Features | ✓6 features | 5 features |
| States Available | ✓50 | 0 |
| Compounded | — | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
GoodRx (Foundayo + Zepbound KwikPen)
Pros
- ✓$149/month self-pay price for FDA-approved brand-name Foundayo (orforglipron) — matches the lowest available discounted cash price at launch and is dramatically cheaper than typical retail brand-GLP-1 pricing
- ✓$299/month self-pay for FDA-approved Zepbound KwikPen — significantly under the typical Lilly cash list price
- ✓Honored at 70,000+ US pharmacies nationwide — by far the largest brick-and-mortar redemption network of any GLP-1 distribution channel we cover
- ✓No telehealth membership fee — you bring your own prescription and present the discount card at the pharmacy counter
- ✓Brand-name FDA-approved medication, not compounded — no compounding-pharmacy quality variability or FDA non-evaluation disclaimer
- ✓Pharmaceutical manufacturer-direct pricing model — Lilly is delivering the discounted cash price directly through GoodRx, not a third-party negotiation
Cons
- ✗Requires a valid prescription — GoodRx is a discount card, not a telehealth provider. You still need a clinician to write the script (your existing PCP, an endocrinologist, or a separate telehealth visit)
- ✗Self-pay only — does not coordinate with insurance benefits or apply toward insurance deductibles
- ✗Pricing applies only to the lowest Foundayo dose at the headline number; higher doses may carry different pricing not disclosed in the launch
- ✗Does not include compounded GLP-1s — if you want compounded semaglutide or tirzepatide, this is not the channel
- ✗GoodRx is publicly traded (NASDAQ: GDRX) and pricing is subject to change as Lilly's manufacturer-sponsored coupon program evolves
ReadyRx
Pros
- ✓LegitScript certified — directly verifiable via the badge link in the footer
- ✓Batch lab testing claim covers four standard QA categories (potency, sterility, pH, endotoxicity) — these are the right metrics for compounded injectables
- ✓Pricing publicly displayed: $179/mo semaglutide, $255/mo tirzepatide
Cons
- ✗Specific FDA-registered pharmacy partner names are not disclosed publicly — claim is generic ('FDA-registered compounding pharmacies')
- ✗Clinical staff are described as 'Licensed, board-certified clinicians' but no individual NPIs or names are published on the homepage
- ✗5,000+ member figure is sourced from a competitor directory, not independently audited
Our Verdict
GoodRx (Foundayo + Zepbound KwikPen) edges out ReadyRx with a higher overall score of 8.4/10 and is particularly strong for self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies. ReadyRx remains a solid alternative, especially if you're looking for compounded GLP-1 buyers who want LegitScript certification and explicit batch lab testing claims at a sub-$200 starting price.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.